Logo Logo
Hilfe
Hilfe
Switch Language to English

Silkenstedt, Elisabeth und Dreyling, Martin (2021): Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches. In: Hematological Oncology, Bd. 39: S. 31-38

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. This review highlights recent advances in deciphering the molecular background of MCL, the definition of prognostically relevant factors and the identification of potential druggable targets and summarizes current treatment recommendations for primary and relapsed/refractory MCL including novel targeted therapies.

Dokument bearbeiten Dokument bearbeiten